Moderna said it is suing Pfizer and its German partner BioNTech for patent infringement linked to the development of the first Covid-19 vaccines. The US biotech company is alleging that mRNA ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Coegi used more than 500 million impressions and paid social optimized with attention and emotion metrics to drive 24% of ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three vaccines available in the U.S.

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...

2 strain of SARS-CoV-2. The approval comes for the updated vaccines from Moderna Inc (NASDAQ:MRNA) and Pfizer Inc (NYSE:PFE) ...

Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax, following in the footsteps of Pfizer/BioNTech, which filed their Comirnaty shot ...

Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent dispute centring on their mRNA-based vaccines for COVID-19. Moderna fired the first volley back in August ...

US pharmaceutical company Moderna Friday sued Pfizer / BioNTech over patent ownership infringement regarding the COVID-19 RNA vaccine “Moderna is convinced that Pfizer and BioNTech's Comirnaty ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...